05Y Stock Chart & Stats
€1.08
<€0.01(0.43%)
At close: 4:00 PM EDT
€1.08
<€0.01(0.43%)
Day’s Range― - ―
52-Week Range€1.02 - €1.78
Previous CloseN/A
Volume0.00
Average Volume (3M)98.00
Market Cap
€33.17M
Enterprise Value€29.61
Total Cash (Recent Filing)€2.45M
Total Debt (Recent Filing)€76.00K
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Dec 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding29,614,338
10 Day Avg. Volume0
30 Day Avg. Volume98
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)8.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage reduces interest obligations and avoids the refinancing pressure associated with heavily indebted businesses. This gives Vivoryon more flexibility to allocate scarce resources toward clinical development, although its overall financial flexibility remains constrained by asset contraction.
Improving Loss And Cash-Burn TrendThe substantial year-over-year improvement in net loss and operating cash outflow suggests that spending or operating efficiency has moved in a more favorable direction. If sustained, lower cash consumption could extend the development runway and reduce the pace of funding needs.
Oral Small-Molecule Clinical PlatformAn oral small-molecule approach can support practical dosing and leverages a defined drug-discovery platform across neurodegenerative and other disease areas. Clinical validation remains necessary, but the platform provides multiple potential development paths from related biological capabilities.
Bears Say
No Recent Revenue And Persistent UnprofitabilityThe absence of recent reported revenue means Vivoryon does not currently demonstrate a recurring commercial income base to support operations. Continued negative gross profit and operating losses make future economics dependent on successful development, partnering, or other external financing.
Persistent Negative Cash GenerationConsistently negative operating and free cash flow shows that the business is not self-funding its research activities. Continued cash consumption can force reliance on external financing or further balance-sheet contraction, potentially limiting the pace and scope of clinical development.
Shrinking Equity And Asset BaseThe sharp reduction in equity and total assets signals that prior cash burn has materially reduced the resources available to fund operations. A smaller capital base lowers resilience to setbacks and may constrain Vivoryon’s ability to sustain programs without new financing.
Vivoryon Therapeutics AG News
05Y FAQ
What was Vivoryon Therapeutics AG’s price range in the past 12 months?
Vivoryon Therapeutics AG lowest stock price was €1.01 and its highest was €1.78 in the past 12 months.
What is Vivoryon Therapeutics AG’s market cap?
Vivoryon Therapeutics AG’s market cap is €33.17M.
When is Vivoryon Therapeutics AG’s upcoming earnings report date?
Vivoryon Therapeutics AG’s upcoming earnings report date is Dec 03, 2026 which is in 87 days.
How were Vivoryon Therapeutics AG’s earnings last quarter?
Vivoryon Therapeutics AG released its earnings results on Aug 06, 2026. The company reported -€0.114 earnings per share for the quarter.
Is Vivoryon Therapeutics AG overvalued?
According to Wall Street analysts Vivoryon Therapeutics AG’s price is currently Overvalued.
Does Vivoryon Therapeutics AG pay dividends?
Vivoryon Therapeutics AG does not currently pay dividends.
What is Vivoryon Therapeutics AG’s EPS estimate?
Vivoryon Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivoryon Therapeutics AG have?
Vivoryon Therapeutics AG has 29,614,338 shares outstanding.
What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
Vivoryon Therapeutics AG reported an EPS of -€0.114 in its last earnings report. Following the earnings report the stock price went up 2.991%.
Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
Currently, no hedge funds are holding shares in DE:05Y
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivoryon Therapeutics AG
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and preventing the formation of toxic pyroglutamate-Abeta (pGlu-Abeta). Its flagship compound, PQ912, a small molecule QC inhibitor, has successfully concluded Phase IIb clinical trials for both Alzheimer's disease and various cancer indications. Additionally, Vivoryon is advancing PQ1565, another small molecule (a glutaminyl-peptide cyclotransferase-like inhibitor), through preclinical development, specifically for cancer therapy. Beyond its small molecule programs, the company is also developing a monoclonal antibody designed to improve the clearance of pGlu-Abeta from the body. To bolster its research and development efforts, Vivoryon has forged several key partnerships, including collaborations with the University Medical Center Schleswig-Holstein for cancer immunotherapy discovery, Nordic Bioscience for the clinical progression of PQ912 in Alzheimer's, and the Fraunhofer Institute for cell therapy and immunology. Furthermore, a significant regional licensing agreement with Simcere Pharmaceutical Group Ltd. aims to develop and commercialize treatments for Alzheimer's disease by targeting the neurotoxic amyloid species N3pE (pGlu-Abeta). Established in 1997, Vivoryon Therapeutics N.V. maintains its headquarters in Halle, Germany.